Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications

Coronavirus disease 2019 (COVID-19) is due to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 which binds and enters the host cells through the angiotensin-converting enzyme (ACE)2. While the potential for benefit with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Triposkiadis, Filippos, Starling, Randall C., Xanthopoulos, Andrew, Butler, Javed, Boudoulas, Harisios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462660/
https://www.ncbi.nlm.nih.gov/pubmed/32875490
http://dx.doi.org/10.1007/s10741-020-10022-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462660/
https://www.ncbi.nlm.nih.gov/pubmed/32875490
http://dx.doi.org/10.1007/s10741-020-10022-4

Ejemplares similares